Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women
Jochen Worsley(Pfizer (United States)), Kristine B. Patterson(University of North Carolina at Chapel Hill), Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Emma Andrews(Pfizer (United States)), Rebecca E. Werner(University of North Carolina at Chapel Hill), Allison L Pecha(University of North Carolina at Chapel Hill), Bharat Damle(Pfizer (United States)), Randall Tressler(National Institute of Allergy and Infectious Diseases), Julie B. Dumond(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
|The Journal of Infectious Diseases|2016|303